Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03992872 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)
A Phase 2 study of Chikungunya, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT03992872 is a Phase 2 study of Chikungunya that has completed, run by Bavarian Nordic. The registered enrollment target is 60 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT03992872, a Phase 2 study of Chikungunya, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
This was a phase 2 parallel-group age- and gender-matched open label study in healthy adults 18-65 years of age to assess the safety and immunogenicity of an alum-adjuvanted chikungunya virus-like particle vaccine (PXVX0317; CHIKV VLP vaccine) in prior recipients of other alphavirus vaccines versus alphavirus naïve controls.
Conditions Studied
Interventions
- BIOLOGICAL Chikungunya
Study Locations (2)
Maryland
- United States Army Medical Research Institute of Infectious Diseases - Fort Deterick
- Walter Reed Army Institute of Research - Silver Spring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2019-11-20 |
| Est. Completion | 2021-01-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03992872
The ClinicalTrials.gov registry entry for NCT03992872 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chikungunya appearing as the primary indexed condition, and to 1 intervention - of which Chikungunya is the first listed.
NCT03992872 reports 2 study locations spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT03992872 about?
NCT03992872 is a clinical study titled "Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)". This was a phase 2 parallel-group age- and gender-matched open label study in healthy adults 18-65 years of age to assess the safety and immunogenicity of an alum-adjuvanted chikungunya virus-like particle vaccine (PXVX0317; CHIKV VLP vaccine) in prior recipients of other alphavirus vaccines versus ...
What is the current status of trial NCT03992872?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2019-11-20. Estimated completion is 2021-01-19.
What conditions does trial NCT03992872 study?
This clinical trial studies the following conditions: Chikungunya.
What interventions are being tested in trial NCT03992872?
The interventions under investigation include: Chikungunya (BIOLOGICAL).
Who is sponsoring clinical trial NCT03992872?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03992872 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chikungunya
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.